Clinical research and the development of medical therapeutics.
Clinical research plays a central role in the development of medical therapeutics, but the current system is estimated to take 10-15 years from initial discovery to regulatory approval, at a cost of approximately US$1 billion. Contrast the paths by which 2 anticoagulant options for atrial fibrillation were discovered and ultimately established as treatment options in clinical medicine. Warfarin was discovered by serendipity and compared with placebo in relatively small trials; this was associated with a low cost of development. The new oral anticoagulants were synthesized to provide highly specific, targeted inhibition of critical steps in the coagulation system. They were compared with warfarin for prevention of stroke and systemic embolic events in large, phase 3 trials; this resulted in very expensive development programs. Neither of these paths is desirable for future development of therapeutics. We need to focus on innovative approaches at the preclinical level (systems approach, greater use of inducible pluripotent stem cells, use of novel bioengineering platforms) and clinical trial level (adaptive design, greater use of new and emerging technology). Focusing on disruptive innovations for development of medical therapeutics has the potential to bring us closer to the goal of precision medicine where safer, more effective treatments are discovered in a more efficient system.
Cardiovascular Division, Brigham and Women's Hospital.
Elliott M
EM
Antman
D000818:Animals; D000925:Anticoagulants / Q000627:therapeutic use*; D035843:Biomedical Research / Q000191:economics / Q000379:methods* / Q000639:trends*; D002318:Cardiovascular Diseases / Q000628:therapy*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D057026:Induced Pluripotent Stem Cells; D033581:Stem Cell Transplantation / Q000379:methods*; D014481:United States
D000925:Anticoagulants